JP5422386B2 - 新規な5,7−二置換された[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン誘導体及び治療におけるその使用 - Google Patents
新規な5,7−二置換された[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン誘導体及び治療におけるその使用 Download PDFInfo
- Publication number
- JP5422386B2 JP5422386B2 JP2009530308A JP2009530308A JP5422386B2 JP 5422386 B2 JP5422386 B2 JP 5422386B2 JP 2009530308 A JP2009530308 A JP 2009530308A JP 2009530308 A JP2009530308 A JP 2009530308A JP 5422386 B2 JP5422386 B2 JP 5422386B2
- Authority
- JP
- Japan
- Prior art keywords
- thiazolo
- compound
- amino
- pyrimidin
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 5,7-disubstituted [1,3] thiazolo [4,5-d] pyrimidin-2 (3H) -one Chemical class 0.000 title description 32
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 181
- 201000006417 multiple sclerosis Diseases 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 48
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 13
- 201000001320 Atherosclerosis Diseases 0.000 claims description 11
- 230000003143 atherosclerotic effect Effects 0.000 claims description 11
- 230000003902 lesion Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- AIYJLSDCPRXTMD-GXSJLCMTSA-N 5-[(1s)-1-(6-chloropyridin-3-yl)ethyl]sulfanyl-7-[[(2r)-1-hydroxypentan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1([C@H](C)SC=2N=C(C=3SC(=O)NC=3N=2)N[C@@H](CO)CCC)=CC=C(Cl)N=C1 AIYJLSDCPRXTMD-GXSJLCMTSA-N 0.000 claims description 5
- 230000007214 atherothrombosis Effects 0.000 claims description 5
- FHEWIRZUHWBRHY-WCQYABFASA-N 2-[(1s)-1-[[7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-2-oxo-3h-[1,3]thiazolo[4,5-d]pyrimidin-5-yl]sulfanyl]ethyl]pyridine-4-carbonitrile Chemical compound C1([C@H](C)SC=2N=C(C=3SC(=O)NC=3N=2)N[C@@H](CO)CC(C)C)=CC(C#N)=CC=N1 FHEWIRZUHWBRHY-WCQYABFASA-N 0.000 claims description 4
- LSHNQYUZVMNJIM-WDEREUQCSA-N 5-[(1s)-1-(3-fluoropyridin-2-yl)ethyl]sulfanyl-7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1([C@H](C)SC=2N=C(C=3SC(=O)NC=3N=2)N[C@@H](CO)CC(C)C)=NC=CC=C1F LSHNQYUZVMNJIM-WDEREUQCSA-N 0.000 claims description 4
- SGVRVKVTFXORDN-CMPLNLGQSA-N 5-[(1s)-1-(5-chloropyridin-2-yl)ethyl]sulfanyl-7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1([C@H](C)SC=2N=C(C=3SC(=O)NC=3N=2)N[C@@H](CO)CC(C)C)=CC=C(Cl)C=N1 SGVRVKVTFXORDN-CMPLNLGQSA-N 0.000 claims description 4
- JEYLBMGUZFBGCY-CMPLNLGQSA-N 5-[(1s)-1-(5-fluoropyridin-2-yl)ethyl]sulfanyl-7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1([C@H](C)SC=2N=C(C=3SC(=O)NC=3N=2)N[C@@H](CO)CC(C)C)=CC=C(F)C=N1 JEYLBMGUZFBGCY-CMPLNLGQSA-N 0.000 claims description 4
- OIZWBJCONDXDLR-CMPLNLGQSA-N 5-[(1s)-1-(6-chloropyridin-3-yl)ethyl]sulfanyl-7-[[(2r)-1-hydroxypentan-2-yl]-methylamino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1([C@H](C)SC=2N=C(C=3SC(=O)NC=3N=2)N(C)[C@@H](CO)CCC)=CC=C(Cl)N=C1 OIZWBJCONDXDLR-CMPLNLGQSA-N 0.000 claims description 4
- OLFXEBNLKOMZBG-RRKGBCIJSA-N 5-[1-(3-fluoropyridin-4-yl)ethylsulfanyl]-7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound N=1C=2NC(=O)SC=2C(N[C@@H](CO)CC(C)C)=NC=1SC(C)C1=CC=NC=C1F OLFXEBNLKOMZBG-RRKGBCIJSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- OLFXEBNLKOMZBG-GHMZBOCLSA-N 5-[(1r)-1-(3-fluoropyridin-4-yl)ethyl]sulfanyl-7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1([C@@H](C)SC=2N=C(C=3SC(=O)NC=3N=2)N[C@@H](CO)CC(C)C)=CC=NC=C1F OLFXEBNLKOMZBG-GHMZBOCLSA-N 0.000 claims description 3
- OLFXEBNLKOMZBG-WDEREUQCSA-N 5-[(1s)-1-(3-fluoropyridin-4-yl)ethyl]sulfanyl-7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1([C@H](C)SC=2N=C(C=3SC(=O)NC=3N=2)N[C@@H](CO)CC(C)C)=CC=NC=C1F OLFXEBNLKOMZBG-WDEREUQCSA-N 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 50
- 239000011541 reaction mixture Substances 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 39
- 238000007429 general method Methods 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 239000000047 product Substances 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 238000003818 flash chromatography Methods 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 235000019439 ethyl acetate Nutrition 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 238000000746 purification Methods 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 239000003480 eluent Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 108010024114 Complement 3b Receptors Proteins 0.000 description 11
- 102000015612 Complement 3b Receptors Human genes 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- MGUHSSFCPTWUHP-NXEZZACHSA-N (2r)-2-[[2-chloro-5-[[2-chloro-7-[[(2r)-1-hydroxypentan-2-yl]amino]-[1,3]thiazolo[4,5-d]pyrimidin-5-yl]disulfanyl]-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]pentan-1-ol Chemical compound CCC[C@H](CO)NC1=C2SC(Cl)=NC2=NC(SSC=2N=C(C=3SC(Cl)=NC=3N=2)N[C@@H](CO)CCC)=N1 MGUHSSFCPTWUHP-NXEZZACHSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 102100030886 Complement receptor type 1 Human genes 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- OGRDDYIZJRCWSP-ZCFIWIBFSA-N 2-amino-7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-4h-[1,3]thiazolo[4,5-d]pyrimidine-5-thione Chemical compound CC(C)C[C@H](CO)NC1=NC(S)=NC2=C1SC(N)=N2 OGRDDYIZJRCWSP-ZCFIWIBFSA-N 0.000 description 5
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 208000016192 Demyelinating disease Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000013818 Fractalkine Human genes 0.000 description 5
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 5
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 description 5
- 230000008485 antagonism Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- OLWSYXWXQLPXCG-YFKPBYRVSA-N (1s)-1-(5-chloropyridin-2-yl)ethanol Chemical compound C[C@H](O)C1=CC=C(Cl)C=N1 OLWSYXWXQLPXCG-YFKPBYRVSA-N 0.000 description 3
- YEOOBRJQYAUNJT-RXMQYKEDSA-N 2-[(1r)-1-chloroethyl]-5-fluoropyridine Chemical compound C[C@@H](Cl)C1=CC=C(F)C=N1 YEOOBRJQYAUNJT-RXMQYKEDSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- SRFMELCSECVOJF-RXMQYKEDSA-N 5-chloro-2-[(1r)-1-chloroethyl]pyridine Chemical compound C[C@@H](Cl)C1=CC=C(Cl)C=N1 SRFMELCSECVOJF-RXMQYKEDSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 0 CC(*)CC(CO)Nc1nc(S)nc2c1[s]c(N)n2 Chemical compound CC(*)CC(CO)Nc1nc(S)nc2c1[s]c(N)n2 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 3
- 229940096397 interleukin-8 Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- AMQJEAYHLZJPGS-UHFFFAOYSA-N n-butyl carbinol Natural products CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JBQSVZVXLQDZRX-YFKPBYRVSA-N (1s)-1-(5-fluoropyridin-2-yl)ethanol Chemical compound C[C@H](O)C1=CC=C(F)C=N1 JBQSVZVXLQDZRX-YFKPBYRVSA-N 0.000 description 2
- PMPXQVZBQKUJRU-YFKPBYRVSA-N (1s)-1-(6-chloropyridin-3-yl)ethanol Chemical compound C[C@H](O)C1=CC=C(Cl)N=C1 PMPXQVZBQKUJRU-YFKPBYRVSA-N 0.000 description 2
- GASYZCCGZHDEEC-ZCFIWIBFSA-N (2r)-2-(ethoxycarbonylamino)pentanoic acid Chemical compound CCC[C@H](C(O)=O)NC(=O)OCC GASYZCCGZHDEEC-ZCFIWIBFSA-N 0.000 description 2
- WCHNLWZGJQDTDD-ZCFIWIBFSA-N (2r)-2-(methylamino)pentan-1-ol Chemical compound CCC[C@H](CO)NC WCHNLWZGJQDTDD-ZCFIWIBFSA-N 0.000 description 2
- UFEVJBBMRPWIKD-WDEREUQCSA-N (2r)-2-[[2-amino-5-[(1s)-1-(3-fluoropyridin-2-yl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CC(C)C)=NC=CC=C1F UFEVJBBMRPWIKD-WDEREUQCSA-N 0.000 description 2
- VSPHPRHMHNAYBJ-UHFFFAOYSA-N 1-(5-fluoropyridin-2-yl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=N1 VSPHPRHMHNAYBJ-UHFFFAOYSA-N 0.000 description 2
- UXSNZYGTQTXRAD-UHFFFAOYSA-N 1-(6-chloropyridin-3-yl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)N=C1 UXSNZYGTQTXRAD-UHFFFAOYSA-N 0.000 description 2
- OKURWHVAGIHTEB-RXMQYKEDSA-N 2-[(1r)-1-chloroethyl]-3-fluoropyridine Chemical compound C[C@@H](Cl)C1=NC=CC=C1F OKURWHVAGIHTEB-RXMQYKEDSA-N 0.000 description 2
- BWSQYAUQJQKVOO-ZCFIWIBFSA-N 2-[(1r)-1-chloroethyl]pyridine-4-carbonitrile Chemical compound C[C@@H](Cl)C1=CC(C#N)=CC=N1 BWSQYAUQJQKVOO-ZCFIWIBFSA-N 0.000 description 2
- SWIPZFANOCNCDM-LURJTMIESA-N 2-[(1s)-1-hydroxyethyl]pyridine-4-carbonitrile Chemical compound C[C@H](O)C1=CC(C#N)=CC=N1 SWIPZFANOCNCDM-LURJTMIESA-N 0.000 description 2
- WISLYNBDMYWHNF-UHFFFAOYSA-N 2-acetylpyridine-4-carbonitrile Chemical compound CC(=O)C1=CC(C#N)=CC=N1 WISLYNBDMYWHNF-UHFFFAOYSA-N 0.000 description 2
- GBQZOTUFSOGDNF-ZCFIWIBFSA-N 2-amino-7-[[(2r)-1-hydroxypentan-2-yl]-methylamino]-4h-[1,3]thiazolo[4,5-d]pyrimidine-5-thione Chemical compound CCC[C@H](CO)N(C)C1=NC(S)=NC2=C1SC(N)=N2 GBQZOTUFSOGDNF-ZCFIWIBFSA-N 0.000 description 2
- UEOCLBUKKVLGJR-RXMQYKEDSA-N 2-chloro-5-[(1r)-1-chloroethyl]pyridine Chemical compound C[C@@H](Cl)C1=CC=C(Cl)N=C1 UEOCLBUKKVLGJR-RXMQYKEDSA-N 0.000 description 2
- ROCKEAUKYWCFGR-VXGBXAGGSA-N 7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-5-[[7-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-2-oxo-3h-[1,3]thiazolo[4,5-d]pyrimidin-5-yl]disulfanyl]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound CC(C)C[C@H](CO)NC1=C2SC(=O)NC2=NC(SSC=2N=C(C=3SC(=O)NC=3N=2)N[C@@H](CO)CC(C)C)=N1 ROCKEAUKYWCFGR-VXGBXAGGSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- VWXJHLSFAQVXJE-YFKPBYRVSA-N (1s)-1-(3-fluoropyridin-2-yl)ethanol Chemical compound C[C@H](O)C1=NC=CC=C1F VWXJHLSFAQVXJE-YFKPBYRVSA-N 0.000 description 1
- ZQYWYNROVIVJQA-BYPYZUCNSA-N (1s)-1-(6-bromo-3-fluoropyridin-2-yl)ethanol Chemical compound C[C@H](O)C1=NC(Br)=CC=C1F ZQYWYNROVIVJQA-BYPYZUCNSA-N 0.000 description 1
- SJVCCIPJTUSTJS-CYBMUJFWSA-N (2r)-2-[(2-amino-5-benzylsulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl)-methylamino]pentan-1-ol Chemical compound N=1C=2N=C(N)SC=2C(N(C)[C@@H](CO)CCC)=NC=1SCC1=CC=CC=C1 SJVCCIPJTUSTJS-CYBMUJFWSA-N 0.000 description 1
- ROMRVRZMWCLQKF-CMPLNLGQSA-N (2r)-2-[[2-amino-5-[(1s)-1-(5-chloropyridin-2-yl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CC(C)C)=CC=C(Cl)C=N1 ROMRVRZMWCLQKF-CMPLNLGQSA-N 0.000 description 1
- NLYAYHBBJYSASQ-CMPLNLGQSA-N (2r)-2-[[2-amino-5-[(1s)-1-(5-fluoropyridin-2-yl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(N)=NC=3N=2)N[C@@H](CO)CC(C)C)=CC=C(F)C=N1 NLYAYHBBJYSASQ-CMPLNLGQSA-N 0.000 description 1
- WKUOZQKYWRDUPE-RRKGBCIJSA-N (2r)-2-[[2-amino-5-[1-(3-fluoropyridin-4-yl)ethylsulfanyl]-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound N=1C=2N=C(N)SC=2C(N[C@@H](CO)CC(C)C)=NC=1SC(C)C1=CC=NC=C1F WKUOZQKYWRDUPE-RRKGBCIJSA-N 0.000 description 1
- BYYXGKPFUPYCPO-WDEREUQCSA-N (2r)-2-[[2-chloro-5-[(1s)-1-(3-fluoropyridin-2-yl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(Cl)=NC=3N=2)N[C@@H](CO)CC(C)C)=NC=CC=C1F BYYXGKPFUPYCPO-WDEREUQCSA-N 0.000 description 1
- GFUCYKPBIUPJFT-CMPLNLGQSA-N (2r)-2-[[2-chloro-5-[(1s)-1-(5-chloropyridin-2-yl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(Cl)=NC=3N=2)N[C@@H](CO)CC(C)C)=CC=C(Cl)C=N1 GFUCYKPBIUPJFT-CMPLNLGQSA-N 0.000 description 1
- PPSNAZHSRNEQSN-CMPLNLGQSA-N (2r)-2-[[2-chloro-5-[(1s)-1-(5-fluoropyridin-2-yl)ethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C(C=3SC(Cl)=NC=3N=2)N[C@@H](CO)CC(C)C)=CC=C(F)C=N1 PPSNAZHSRNEQSN-CMPLNLGQSA-N 0.000 description 1
- QWHMAJFNXOONMC-RRKGBCIJSA-N (2r)-2-[[2-chloro-5-[1-(3-fluoropyridin-4-yl)ethylsulfanyl]-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound N=1C=2N=C(Cl)SC=2C(N[C@@H](CO)CC(C)C)=NC=1SC(C)C1=CC=NC=C1F QWHMAJFNXOONMC-RRKGBCIJSA-N 0.000 description 1
- LCKLZGKFPGECBG-VXGBXAGGSA-N (2r)-2-[[2-chloro-5-[[2-chloro-7-[[(2r)-1-hydroxypentan-2-yl]-methylamino]-[1,3]thiazolo[4,5-d]pyrimidin-5-yl]disulfanyl]-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]-methylamino]pentan-1-ol Chemical compound CCC[C@H](CO)N(C)C1=C2SC(Cl)=NC2=NC(SSC=2N=C(C=3SC(Cl)=NC=3N=2)N(C)[C@@H](CO)CCC)=N1 LCKLZGKFPGECBG-VXGBXAGGSA-N 0.000 description 1
- BIIJNTWZQPFGAW-NWDGAFQWSA-N (2r)-2-[[5-[(1s)-1-(3-fluoropyridin-2-yl)ethyl]sulfanyl-2-methoxy-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C3N=C(SC3=C(N[C@@H](CO)CC(C)C)N=2)OC)=NC=CC=C1F BIIJNTWZQPFGAW-NWDGAFQWSA-N 0.000 description 1
- IUSUYGBYPJRLBV-WCQYABFASA-N (2r)-2-[[5-[(1s)-1-(5-chloropyridin-2-yl)ethyl]sulfanyl-2-methoxy-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C3N=C(SC3=C(N[C@@H](CO)CC(C)C)N=2)OC)=CC=C(Cl)C=N1 IUSUYGBYPJRLBV-WCQYABFASA-N 0.000 description 1
- ARNGDPLHHYGLKR-WCQYABFASA-N (2r)-2-[[5-[(1s)-1-(5-fluoropyridin-2-yl)ethyl]sulfanyl-2-methoxy-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound C1([C@H](C)SC=2N=C3N=C(SC3=C(N[C@@H](CO)CC(C)C)N=2)OC)=CC=C(F)C=N1 ARNGDPLHHYGLKR-WCQYABFASA-N 0.000 description 1
- BSIBENFEJYRIST-PIJUOVFKSA-N (2r)-2-[[5-[1-(3-fluoropyridin-4-yl)ethylsulfanyl]-2-methoxy-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol Chemical compound N=1C(N[C@@H](CO)CC(C)C)=C2SC(OC)=NC2=NC=1SC(C)C1=CC=NC=C1F BSIBENFEJYRIST-PIJUOVFKSA-N 0.000 description 1
- ULAXUFGARZZKTK-RXMQYKEDSA-N (2r)-2-aminopentan-1-ol Chemical compound CCC[C@@H](N)CO ULAXUFGARZZKTK-RXMQYKEDSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- VMKAFJQFKBASMU-QGZVFWFLSA-N (r)-2-methyl-cbs-oxazaborolidine Chemical compound C([C@@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-QGZVFWFLSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- NCZUOSCEVQLKCR-UHFFFAOYSA-N 1-(3-fluoropyridin-4-yl)ethanol Chemical compound CC(O)C1=CC=NC=C1F NCZUOSCEVQLKCR-UHFFFAOYSA-N 0.000 description 1
- VVYMEQBXUFPILB-UHFFFAOYSA-N 1-(5-chloropyridin-2-yl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=N1 VVYMEQBXUFPILB-UHFFFAOYSA-N 0.000 description 1
- MXBFVOYREPRONK-UHFFFAOYSA-N 1-(6-bromo-3-fluoropyridin-2-yl)ethanone Chemical compound CC(=O)C1=NC(Br)=CC=C1F MXBFVOYREPRONK-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- RKGYXEVHTDVBLJ-RXMQYKEDSA-N 2-amino-7-[[(2r)-1-hydroxypentan-2-yl]amino]-4h-[1,3]thiazolo[4,5-d]pyrimidine-5-thione Chemical compound N1C(=S)N=C2N=C(N)SC2=C1N[C@@H](CO)CCC RKGYXEVHTDVBLJ-RXMQYKEDSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DCSLKYLPOSSKFY-UHFFFAOYSA-N 3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound C1=NC=C2SC(=O)NC2=N1 DCSLKYLPOSSKFY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MQLADKMVHOOVET-HXPMCKFVSA-N 5-[4-[(2s,4r)-4-hydroxy-2-methyloxan-4-yl]thiophen-2-yl]sulfanyl-1-methyl-3h-indol-2-one Chemical compound C1CO[C@@H](C)C[C@@]1(O)C1=CSC(SC=2C=C3CC(=O)N(C)C3=CC=2)=C1 MQLADKMVHOOVET-HXPMCKFVSA-N 0.000 description 1
- SJNSPSXSWUZBQZ-UHFFFAOYSA-N 5-benzylsulfanyl-7-chloro-[1,3]thiazolo[4,5-d]pyrimidin-2-amine Chemical compound N=1C(Cl)=C2SC(N)=NC2=NC=1SCC1=CC=CC=C1 SJNSPSXSWUZBQZ-UHFFFAOYSA-N 0.000 description 1
- BHXHRMVSUUPOLX-UHFFFAOYSA-N 5-fluoropyridine-2-carbonitrile Chemical compound FC1=CC=C(C#N)N=C1 BHXHRMVSUUPOLX-UHFFFAOYSA-N 0.000 description 1
- 239000003406 5-lipoxygenase-activating protein inhibitor Substances 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 102100038495 Bile acid receptor Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- OIZWBJCONDXDLR-UHFFFAOYSA-N CCCC(CO)N(C)c1nc(SC(C)c(cc2)cnc2Cl)nc(N2)c1SC2=O Chemical compound CCCC(CO)N(C)c1nc(SC(C)c(cc2)cnc2Cl)nc(N2)c1SC2=O OIZWBJCONDXDLR-UHFFFAOYSA-N 0.000 description 1
- AIYJLSDCPRXTMD-HCCKASOXSA-N CCC[C@H](CO)Nc(nc(nc1N2)SC(C)c(cc3)cnc3Cl)c1SC2=O Chemical compound CCC[C@H](CO)Nc(nc(nc1N2)SC(C)c(cc3)cnc3Cl)c1SC2=O AIYJLSDCPRXTMD-HCCKASOXSA-N 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- SNDPXSYFESPGGJ-SCSAIBSYSA-N D-2-aminopentanoic acid Chemical compound CCC[C@@H](N)C(O)=O SNDPXSYFESPGGJ-SCSAIBSYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000916059 Homo sapiens C-X-C chemokine receptor type 2 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 1
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- 229940122159 Myeloperoxidase inhibitor Drugs 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- YINHYQCZTGQCGH-LURJTMIESA-N NC=1SC2=C(N=C(N=C2)S[C@@H](C)C2=NC=C(C=C2)Cl)N1 Chemical compound NC=1SC2=C(N=C(N=C2)S[C@@H](C)C2=NC=C(C=C2)Cl)N1 YINHYQCZTGQCGH-LURJTMIESA-N 0.000 description 1
- RAQPYNWMRIEOSY-LURJTMIESA-N NC=1SC2=C(N=C(N=C2)S[C@@H](C)C2=NC=C(C=C2)F)N1 Chemical compound NC=1SC2=C(N=C(N=C2)S[C@@H](C)C2=NC=C(C=C2)F)N1 RAQPYNWMRIEOSY-LURJTMIESA-N 0.000 description 1
- AHBYFBLHUXZBAW-LURJTMIESA-N NC=1SC2=C(N=C(N=C2)S[C@@H](C)C2=NC=CC=C2F)N1 Chemical compound NC=1SC2=C(N=C(N=C2)S[C@@H](C)C2=NC=CC=C2F)N1 AHBYFBLHUXZBAW-LURJTMIESA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- YWBULOYFCXZCGF-UHFFFAOYSA-N [1,3]thiazolo[4,5-d]pyrimidine Chemical class C1=NC=C2SC=NC2=N1 YWBULOYFCXZCGF-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- PSEHHVRCDVOTID-UHFFFAOYSA-N chloro-bis(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)borane Chemical compound CC1C(C2(C)C)CC2CC1B(Cl)C(C1C)CC2C(C)(C)C1C2 PSEHHVRCDVOTID-UHFFFAOYSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- XFLQIRAKKLNXRQ-UUWRZZSWSA-N elobixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C=3C=CC=CC=3)C=C2S(=O)(=O)CC(CCCC)(CCCC)CN1C1=CC=CC=C1 XFLQIRAKKLNXRQ-UUWRZZSWSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000057105 human CX3CL1 Human genes 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 102000055357 human CXCR2 Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 229950001135 muraglitazar Drugs 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000003428 phospholipase inhibitor Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000008634 thiazolopyrimidines Chemical group 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 1
- 229960001522 ximelagatran Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Description
R1は、CH3又はCF3を表し;
R2は、ハロ、CN又はC1-6アルキルを表し;
R3は、H又はCH3を表し;
R4は、H又はCH3を表し;
nは、0、1又は2を表す)
の化合物又はその医薬上許容しうる塩、溶媒和物若しくは塩の溶媒和物を提供する。
5−{[(1S)−1−(5−クロロピリジン−2−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[(1S)−1−(5−フルオロピリジン−2−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[1−(3−フルオロピリジン−4−イル)エチル]チオ}−7{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[(1S)−1−(3−フルオロピリジン−4−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[(1R)−1−(3−フルオロピリジン−4−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[(1S)−1−(3−フルオロピリジン−2−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
2−{(1S)−1−[(7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}−2−オキソ−2,3−ジヒドロ[1,3]チアゾロ[4,5−d]ピリミジン−5−イル)チオ]エチル}イソニコチノニトリル;
5−{[(1S)−1−(6−クロロピリジン−3−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)ブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;及び
5−{[(1S)−1−(6−クロロピリジン−3−イル)エチル]チオ}−7−[[(1R)−1−(ヒドロキシメチル)ブチル](メチル)アミノ][1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
から選ばれる式(I)の化合物又はその医薬上許容しうる塩、溶媒和物若しくは塩の溶媒和物が提供される。
a)式(II):
式(III):
そして必要に応じて、生成した式(I)の化合物、又はその別の塩を、その医薬上許容しうる塩に転換するか;又は生成した式(I)の化合物をさらなる式(I)の化合物に転換し;そして所望により、生成した式(I)の化合物をその光学異性体に転換することを含む、
式(I)の化合物又はその医薬上許容しうる塩の製造方法を提供する。
1) 抗炎症剤、例えば、
a) NSAID(例えばアセチルサリチル酸、イブプロフェン、ナプロキセン、フルルビプロフェン、ジクロフェナク、インドメタシン);
b) ロイコトリエン合成阻害剤(5−LO阻害剤、例えばAZD4407、ジレウトン、リコフェロン、CJ13610、CJ13454);FLAP阻害剤、例えばBAY−Y−1015、DG−031、MK591、MK886、A81834;LTA4ヒドロラーゼ阻害剤、例えばSC56938、SC57461A);
c) ロイコトリエン受容体アンタゴニスト;(例えば、CP195543、アメルバント、LY293111、アコレート、MK571);
2)抗高血圧剤、例えば、
a) ベータ遮断剤(例えばメトプロロール、アテノロール、ソタロール);
b) アンギオテンシン変換酵素阻害剤(例えばカプトプリル、ラミプリル、キナプリル、エナラプリル);
c) カルシウムチャネル遮断剤(例えばベラパミル、ジルチアゼム、フェロジピン、アムロジピン);
d) アンギオテンシンII受容体アンタゴニスト(例えばイルベサルタン、カンデサルタン、テレミサルタン(telemisartan)、ロサルタン);
3)抗血液凝固剤(anti−coagulantia)、例えば、
a) トロンビン阻害剤(例えばキシメラガトラン)、ヘパリン、第Xa因子阻害剤;
b) 血小板凝集阻害剤(例えば、クロピドロゲル、チクロピジン、プラスゲル、AZ4160);
4)脂質代謝のモジュレーター、例えば、
a) インスリン増感剤、例えばPPARアゴニスト(例えばピオグリタゾン、ロシグリタゾン、ガリダ、ムラグリタザール、ゲフェムロジル(gefemrozil)、フェノフィブレート);
b) HMG−CoAレダクターゼ阻害剤、スタチン(例えば、シンバスタチン、プラバスタチン、アトルバスタチン、ロスバスタチン、フルバスタチン、ピタバスタチン);
c) コレステロール吸収阻害剤(例えばエゼチミブ);
d) IBAT阻害剤(例えばAZD−7806);
e) LXRアゴニスト(例えばGW−683965A、T−0901317);
f) FXR受容体モジュレーター;
g) ホスホリパーゼ阻害剤;
5)抗狭心症剤(例えばニトラート及びニトリット);
6)酸化的ストレスのモジュレーター、例えば、抗酸化剤(プロブコール)、ミエロペルオキシダーゼ阻害剤。
一般的な方法
使用した全ての溶媒は、分析グレードであり、そして商業的に入手可能な無水溶媒を、常法により反応に使用した。反応は、典型的に窒素又はアルゴンの不活性雰囲気下で実施した。1H及び13C NMRスペクトルは、Z−勾配を有する5mmのBBOプローブを備えたVarian
Unity+ 400 NMR分光計、又はZ−勾配を有する60μlデュアルインバーズフロープローブを備えたBruker Avance 400 NMR分光計、又はZ−勾配を有する4−核プローブを備えたBruker DPX400 NMR分光計のいずれかにおいて、プロトンについては400MHzで、そして炭素−13については100MHzで記録した。600MHzの1H NMRスペクトルは、Z−勾配を有する5mmのBBIプローブヘッドを備えたBruker av600 NMR分光計で記録した。300MHzの1H NMRスペクトルは、5mmのBBI プローブヘッドを備えたVarian Gemini 300 NMRで記録した。500 MHzの1H NMRスペクトルは、5mmの核勾配プローブを備えたVarian Inova 500分光計を11.74 Tの磁場で操作して記録した。実施例に特に明記しない限り、プロトンについては400MHz、そして炭素−13については100MHzでスペクトルを記録した。以下の基準シグナルを用いた:DMSO−d6の中間線 δ 2.50(1H), δ 39.51(13C);CD3ODの中間の線δ3.31(1H)又はδ49.15(13C);アセトン−d6 2.04(1H), 206.5(13C);及びCDCl3δ7.26(1H)、CDCl3の中間線δ 77.16(13C)(特に明記しない限り)。
(2R)−2−[(2−アミノ−5−メルカプト[1,3]チアゾロ[4,5−d]ピリミジン−7−イル)アミノ]−4−メチルペンタン−1−オール:WO 02/076990(実施例1〜4);
5−(ベンジルチオ)−7−クロロ[1,3]チアゾロ[4,5−d]ピリミジン−2−アミン:WO 00/09511(実施例6及び7);
5−フルオ−ロピリジン−2−カルボニトリル:WO 2005/066155(実施例2);
1−(3−フルオロピリジン−4−イル)エタノール:Marsais, F. et al. Tetrahedron
1983, 39, 2009-2021 (実施例3);
2−アセチル−イソニコチノニトリル:Citterio et al. J. Chem. Res. Synopses 1982,
10, 272−273(実施例5);
1−(6−クロロピリジン−3−イル)エタノン:Lee, C. et al. J. Med. Chem. 2001,
44, 2133(実施例6及び7)。
yは、場合により置換されたピリジルを表し、そしてLGは脱離基を表す。
(R)−(+)−2−メチル−CBS−オキサザボロリジン(トルエン中1M,0.1−1当量)をTHF中に溶解し、そして0℃に冷却した。ボラン−メチルスルフィド錯体(THF中2M,1当量)を滴加し、そして反応混合物を1時間撹拌した。反応混合物を−10℃に冷却し、そしてTHF中に溶解した(VIII)(1当量)を0.5時間かけて滴加した。生成した混合物を1時間、又は反応が完了するまで撹拌し、そして温度を10℃にゆっくりと高めた。1M水性HClを加えて反応をクエンチした。pHが約8になるまで、飽和水性NaHCO3を加えた。生成物をDCMで抽出した。合わせた有機抽出物をNa2SO4で乾燥させ、そして真空で濃縮して(X)を得た。生成物を、カラムクロマトグラフィによって場合により精製した。
塩化シアヌリル(0.6当量)を酢酸エチル中に溶解した。DMF(1.5当量)を加え、そして混合物を室温で10分間撹拌した。反応混合物を0℃に冷却した。(IX)又は(X)(1当量)を酢酸エチル中に溶解し、そして10分の間に滴加した。生成した混合物を室温で一夜撹拌した。イソプロパノール(約0.25mL/mmol(IX)又は(X))を加えた。沈殿を濾過し、そしてEtOAcで洗浄した。濾液を濃縮して(XI)又は(XII)を得た。
5−{[(1S)−1−(5−クロロピリジン−2−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン
1H NMR (300 MHz, CDCl3) δ ppm 8.62 (m, 1H); 8.00 (m, 1H); 7.80 (m, 1H); 2.70 (s, 3H).
1H NMR (300 MHz, CDCl3): 8.47 (s, 1H); 7.65 (d, 1H); 7.26 (d, 1H); 4.87 (q, 1H);
3.87 (br s, 1H); 1.47 (d, 3H); MS (ESI) m/z 140 及び142 [M+1]+.
1H NMR (400 MHz, CDCl3): δ ppm 8.46 (d, 1 H), 7.64 (dd, 1 H), 7.41 (d, 1 H), 5.08 (q, 1 H), 1.80 (d, 3 H); MS (ESI) m/z 176 及び 178 [M+1]+.
1H NMR (400 MHz, CD3OD): δ ppm 8.49 (d, 1 H), 7.79 (dd, 1 H), 7.66 (d, 1 H), 5.22 (q, 1 H), 4.46 (br s, 1 H), 3.40−3.57 (m, 2 H), 1.66−1.78 (m, 4 H), 1.40−1.61 (m, 2 H), 0.93−1.03 (m, 6 H); MS (ESI) m/z 439 及び 441 [M+1]+.
MS (ESI) m/z 458 及び460 [M+1]+.
MS (ESI) m/z 453 及び 455 [M+1]+.
1H NMR (400 MHz, CD3OD): δ ppm 8.24 (d, 1 H), 7.56 (dd, 1 H), 7.38 (d, 1 H), 4.90 (q, 1 H), 4.19 (br s, 1 H), 3.16−3.30 (m, 2 H), 1.39−1.51 (m, 4 H), 1.15−1.34 (m, 2 H), 0.68−0.76 (m, 6 H);1H NMR (DMSO−d6) δ ppm 12.36 (br s, 1H), 8.57 (d, 1H), 7.86 (dd, 1H); 7.57 (d, 1H); 7.23 (d, 1H); 5.03 (q, 1H); 4.69 (t, 1H); 4.29 (br s, 1H); 3.40−3.25 (m, 2H), 1.66 (d, 3H), 1.63−1.52 (m, 1H); 1.48−1.32 (m, 2H), 0.88 (d, 3H), 0.85 (d, 3H);MS (ESI) m/z 440 及び442 [M+1]+, 438 及び440 [M−1]+ .
5−{[(1S)−1−(5−フルオロピリジン−2−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン
1H NMR (300 MHz, CDCl3): 8.50 (m, 1H); 8.10 (m, 1H); 7.52 (m, 1H); 2.70 (s, 3H).
1H NMR (300 MHz, CDCl3): 8.38 (m, 1H); 7.5−7.2 (m, 2H); 4.89 (q, 1H); 3.9 (br s, 1H); 1.49 (d, 3H).
1H NMR (300 MHz, CDCl3): 8.44−8.40 (m, 1H); 7.6−7.4 (m, 2H); 5.16 (q, 1H), 1.86 (d, 3H).
1H NMR (400 MHz, DMSO−d6) δ ppm 8.51 (d, 1H), 7.98 (s, 2H), 7.65 (dt, 1H); 7.58 (dd, 1H), 6.88 (d, 1H); 5.12 (q, 1H); 4.66 (t, 1H); 4.27 (br s, 1H); 3.41−3.27 (m, 2H), 1.66 (d, 3H), 1.65−1.55 (m, 1H); 1.48−1.35 (m, 2H), 0.88 (d, 3H), 0.85 (d, 3H); MS (ESI) m/z 423 [M+1]+.
MS (ESI) m/z 442 及び444 [M+1]+.
MS (ESI) m/z 438 [M+1]+.
1H NMR (CD3OD): δ ppm 8.19 (d, 1 H), 7.46 (dd, 1 H), 7.36 (dt, 1 H), 4.97 (q, 1 H), 4.26 (br s, 1 H), 3.23−3.34 (m, 2 H), 1.44−1.55 (m, 4 H), 1.19−1.37 (m, 2 H), 0.75 (dd, 6 H);1H NMR (DMSO−d6) δ ppm 12.36 (br s, 1H), 8.52 (d, 1H), 7.66 (dt, 1H); 7.60 (dd, 1H), 7.23 (d, 1H); 5.07 (q, 1H); 4.69 (t, 1H); 4.30 (br s, 1H); 3.40−3.26 (m, 2H), 1.67 (d, 3H), 1.64−1.53 (m, 1H); 1.48−1.33 (m, 2H), 0.88 (d, 3H), 0.85 (d, 3H); MS (ESI) m/z 424 [M+1]+. OK
5−{[1−(3−フルオロピリジン−4−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン
1H NMR (300 MHz, CDCl3) 8.45 (m, 2H), 7.50 (m, 1H), 5.34 (q, 1H), 1.83 (d, 3H).
MS (ESI) m/z 423 [M+1]+.
MS (ESI) m/z 424 [M+1]+.
5−{[(1S)−1−(3−フルオロピリジン−2−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン
1H NMR (300 MHz, DMSO−d6): 8.0−7.8 (m, 2H); 2.57 (s, 3H); MS (ESI) m/z 218 及び220 [M+1]+.
1H NMR (300 MHz, CDCl3) 7.38 (m, 1H); 7.26 (m, 1H); 5.06 (q, 1H); 3.38 (br s, 1H); 1.47 (d, 3H); MS (ESI) m/z 220 及び 222 [M+1]+, m/z 202 [M−H2O]+.
1H NMR (300 MHz, CDCl3): 8.38 (m, 1H); 7.39 (m, 1H); 7.26 (m, 1H); 5.11 (q, 1H);
4.16 (br s, 1H); 1.49 (d, 3H).
1H NMR (300 MHz, CDCl3): 8.46 (m, 1H); 7.47 (m, 1H); 7.34 (m, 1H); 5.48 (q, 1H),
1.94 (d, 3H); MS (ESI) m/z 160 及び 162 [M+1]+.
1H NMR (400 MHz, DMSO−d6) δ ppm 8.40 (dt, 1H), 7.98 (s, 2H), 7.70 (m, 1H), 7.40 (m, 1H); 6.92 (d, 1H); 5.45 (q, 1H); 4.65 (t, 1H); 4.27 (br s, 1H); 3.45−3.30 (m, 2H), 1.69 (d, 3H), 1.66−1.58 (m, 1H), 1.50−1.35 (m, 2H), 0.88 (d, 3H), 0.85 (d, 3H); MS (ESI) m/z 423 [M+1]+. MS (ESI) m/z 423 [M+1]+.
MS (ESI) m/z 442 及び 444 [M+1]+.
MS (ESI) m/z 438 [M+1]+.
1H NMR (DMSO−d6) δ ppm 12.37 (br s, 1H), 8.41 (dt, 1H), 7.72 (m, 1H); 7.42 (m, 1H); 7.27 (br s, 1H); 5.43 (q, 1H); 4.67 (t, 1H); 4.30 (br s, 1H); 3.44−3.30 (m, 2H), 1.70 (d, 3H), 1.65−1.55 (m, 1H); 1.52−1.32 (m, 2H), 0.89 (d, 3H), 0.86 (d, 3H); MS (ESI) m/z 424 [M+1]+.
2−{(1S)−1−[(7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}−2−オキソ−2,3−ジヒドロ[1,3]チアゾロ[4,5−d]ピリミジン−5−イル)チオ]エチル}イソニコチノニトリル
1H NMR (500 MHz, CDCl3) δ 8.72 (d, 1H), 7.62 (s, 1H), 7.44 (dd, 1H), 4.96 (q, 1
H), 1.54 (d, 3H).
1H NMR (500 MHz, CDCl3) δ 8.74 (d, 1H), 7.76 (s, 1H), 7.46 (dd, 1H), 5.16 (q, 1H), 1.88 (d, 3H).
1H NMR (DMSO−d6) δ 8.25 (d, 2H), 4.19 (m, 2H), 3.35 (m, 4H), 1.40 (m, 4H), 1.21 (m, 2H), 0.68 (d, 6H), 0.51 (d, 6H); MS (ESI) m/z 635 [M+1]+.
MS (ESI) m/z 627 [M+1]+.
1H NMR (DMSO−d6) δ 12.45 (s, 2H), 7.33 (d, 2H), 4.62 (t, 2H), 4.17 (br s, 2H),
1.48−1.31 (m, 4H), 1.25−1.14 (m, 2H), 0.72 (d, 6H), 0.56 (d, 6H); MS (ESI) m/z 599 [M+1]+.
1H NMR (500 MHz, CD3OD) δ 8.71 (d, 1H), 7.92 (s, 1H), 7.56 (d, 1H), 5.17 (q, 1H), 4.4 (s, 1H), 3.40−3.52 (m, 2H), 1.72 (d 3H), 1.60−1.71 (m 1H), 1.38−1.54 (m, 2H), 0.90−0.98 (m 6H); MS (ESI+) m/z 431 [M+H]+.
MS (ESI+) m/z 376 [M+H]+.
MS (ESI+) m/z 286 [M+H]+.
1H NMR (DMSO−d6) δ 8.27 (d, 1H), 4.32−3.81 (m, 2H), 3.50−3.23 (m, 2H), 1.37−1.19 (m, 2H), 1.10−0.93 (m, 1H), 0.94−0.78 (m, 1H), 0.49 (t, 3H); MS (ESI) m/z 607 [M+1]+.
MS (ESI) m/z 599 [M+1]+.
1H NMR (DMSO−d6) δ 12.46 (s, 1H), 7.33 (d, 1H), 4.61 (t, 1H), 4.10 (br. s., 1H), 3.35 (t, 2H), 1.37−1.20 (m, 2H), 1.13−1.10 (m, 1H), 0.96−0.82 (m, 1H), 0.59 (t, 3H); MS (ESI) m/z 571 [M+1]+.
1H NMR (CDCl3) δ ppm 8.40−8.28 (m, 1H), 7.75−7.63 (m, 1H), 7.35−7.24 (m, 1H), 5.04−4.79 (m, 1H), 1.63−1.45 (m, 3H); MS (ESI) m/z 158 and 160 [M+1]+.
1H NMR (CDCl3) δ ppm 8.45−8.35 (m, 1H), 7.79−7.70 (m, 1H), 7.39−7.29 (m, 1H), 5.07 (q, 1H), 1.85−1.78 (m, 3H); MS (ESI) m/z 176 及び178 [M+1]+.
1H NMR (CDCl3) δ ppm 8.52−8.38 (m, 1H), 7.87−7.72 (m, 1H), 7.30−7.26 (m, 1H), 4.91−4.81 (m, 1H), 4.74−4.65 (m, 1H), 4.29−4.17 (m, 1H), 3.68−3.52 (m, 2H), 1.69−1.64 (m, 3H), 1.56−1.46 (m, 2H), 1.46−1.32 (m, 2H), 0.98−0.90 (m, 3H); MS (ESI) m/z 426 及び 428 [M+1]+.
5−{[(1S)−1−(6−クロロピリジン−3−イル)エチル]チオ}−7−[[(1R)−1−(ヒドロキシメチル)ブチル](メチル)アミノ][1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン
1H NMR (CDCl3) δ ppm 6.43 (br s, 1H), 5.22 (d, 1H), 4.37 (q, 1H), 4.13 (q, 2H),
1.84 (m, 1H), 1.68 (六重線, 1H), 1.42 (六重線, 1H), 1.25 (t, 3H), 0.95 (t, 3H);
MS (CI) 144 (100%), 190 [M+1]+.
1H NMR (CDCl3) 3.63 (dd, 1H); 3.30 (dd, 1H); 2.51 (m, 1H); 2.41 (s, 3H); 2.09 (br s, 2H); 1.50−1.28 (m, 4H); 0.93 (t, 3H); MS (CI) 86 (100%), 118 [M+1]+.
1H NMR (DMSO−d6) 7.98 (br s, 2H), 7.41 (m, 2H), 7.29 (m, 2H), 7.22 (m, 1H), 4.73 (t, 1H), 4.54 (br s, 1H), 4.33 (m, 2H), 3.55−3.40 (m, 2H), 3.01 (s, 3H), 1.52−1.44 (m, 2H), 1.25−1.10 (m, 2H), 0.84 (t, 3H); MS (ESI) m/z 390 [M+1]+.
1H NMR (DMSO−d6) 12.81 (br s, 1H); 8.45 (br s, 2H), 4.84 (br s, 1H), 3.55−3.40 (m, 2H), 3.02 (s, 3H), 1.48 (m, 2H), 1.21 (m, 2H), 0.87 (t, 3H); MS (ESI) m/z 300 [M+1]+.
MS (ESI) m/z 635 及び637 [M+1]+.
MS (ESI) m/z 627 [M+1]+.
MS (ESI) m/z 599 [M+1]+.
1H NMR (CDCl3) δ ppm 8.56−8.38 (m, 1H), 7.87−7.73 (m, 1H), 7.28−7.26 (m, 1H), 4.86 (q, 1H), 4.75−4.62 (m, 1H), 3.76−3.55 (m, 3H), 3.03 (s, 3H), 1.70−1.63 (m, 3H), 1.53−1.45 (m, 2H), 1.26−1.21 (m, 2H), 0.95−0.88 (m, 3H); MS (ESI) m/z 440 及び 442 [M+1]+.
実施例8a
5−{[(1R)−1−(3−フルオロピリジン−4−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン及び
実施例8b
5−{[(1S)−1−(3−フルオロピリジン−4−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン
1H NMR (DMSO−d6) δ ppm 12.31 (br s, 1H), 8.51 (m, 1H), 8.38 (d, 1H); 7.62 (m, 1H); 6.97 (br s, 1H); 5.16 (q, 1H); 4.66 (t, 1H); 4.12 (m, 1H); 3.44−3.30 (m, 2H,水のシグナルによって不明瞭であった), 1.66 (d, 3H), 1.61−1.27 (m, 3H), 0.84 (d, 3H), 0.74 (d, 3H); MS (ESI) m/z 424 [M+1]+.
及び最後に溶出する異性体45mgを得た:
1H NMR (DMSO−d6) δ ppm 12.35 (br s, 1H), 8.52 (d, 1H), 8.38 (d, 1H); 7.62 (dd,
1H); 7.12 (br s, 1H); 5.15 (q, 1H); 4.62 (t, 1H); 4.21 (m, 1H); 3.35−3.15 (m, 2H, 水のシグナルによって部分的に不明瞭であった), 1.65 (d, 3H), 1.63−1.29 (m, 3H), 0.88 (d, 3H), 0.85 (d, 3H); MS (ESI) m/z 424 [M+1]+.
物質
組換え型ヒトフラクタルカイン(hCX3CL1)及び組換え型ヒトインターロイキン−8(IL−8又はhCXCL8)を、PeproTech Inc., UK.から購入した。組換え型[125I]−フラクタルカイン(ヒト)及び2200Ci/mmolの比活性を有する[125I] hIL−8を、NEN(R) Life Science Products, Inc., UK.から購入した。Fluo4−AMを、Molecular Probes, US.から購入した。他の全ての化学物質は、分析グレードであった。
完全ヒトCX3CR1 cDNA(GenBank受託番号U20350)をヒト脳mRNA (Superscript, Life Technologies)から抽出し、そしてpCR−Blunt II TOPOベクター(InVitrogen)に結合した。hCX3CR1に対応する挿入断片を単離し、そしてさらにpcDNA3.1zeo中にサブクローニングした。プラスミドDNAは、Plasmid Midi Kit (Qiagen)を用いて製造した。次いで、製造者のプロトコールに従ってSuperfect Transfection Reagent (Qiagen)を用いてhCX3CR1の発現プラスミドを、キメラG−タンパク質Gαqi5を安定に発現するベクターを含むヒト胎生腎懸濁液(HEKS)293細胞系に導入した。ゼオシン(500μg/mL)及びハイグロマイシン(100μg/mL)選択を利用して安定なクローンを生成した。さらなる適用のため、ピリドキシンを含み、そして10%(v/v)ウシ胎児血清、2mM L−グルタミン、100U/mlペニシリン及び100mg/mlストレプトマイシン、250μg/mLゼオシン及び100μg/mLハイグロマイシンを補足したダルベッコ変法イーグル培地/ハム(Ham's nutrient mix)F12(DMEM/F12)中に細胞を維持した。
細胞を37℃及び5%CO2で成長させ、そして10mMトリス−HCl pH7.4、5mM EDTA、0.1mg/mlバシトラシンを含む緩衝液中で、60〜80%集密で収穫した。細胞を300xgで10分間遠心分離し、そしてペレットを収穫緩衝液(harvesting buffer)(10mMトリス−HCl,pH7.4、5mMエチレンジアミン四酢酸(EDTA)及び0.1mg/mlバシトラシン)中に再懸濁し、プールし、そしてDounceホモジナイザーを用いて均質化した。ホモジネートを48000xgで10分間遠心分離し、そしてUltra−Turrax T8を用いて収穫緩衝液中に再懸濁した。膜アリコートを−80℃で保存した。Harringtonによって記載されたようにマイクロタイタープレート中でタンパク質濃度を測定した(1990, Anal. Biochem. 186, 285−287)。
[125I]フラクタルカインの競合結合研究を総容積1000μL/ウェルの2mL96ディープウェルプレート(Beckman, Germany)中で実施した。各ウェルには、アッセイ緩衝液(50mM Hepes−KOH,pH7.4,10mM MgCl2,1mM EDTA,0.1%(w/v)ゼラチン)中に10pM[125I]−フラクタルカイン、及び1pMの受容体濃度と同等の膜が含まれる。10種の濃度(2点/ログ単位)の試験化合物をDMSO中に予め溶解し、そして加えて1%(v/v)DMSOの最終濃度に到達させた。膜を添加してアッセイを開始し、そして25℃で24時間インキュベートした。0.3%ポリエチルイミンで前処理したWhatman GF/Bガラス繊維フィルタを通して急速濾過することによって反応を停止し、その後、Brandel受容体結合収穫器を用いて氷冷緩衝液(10mM Hepes−KOH pH7.4,500mM NaCl)で洗浄した。シンチレーションカクテルを加え、そしてPackard 2500TR液体シンチレーションカウンター(Perkin Elmer, USA)で放射活性を測定した。
[35S]GTPγS結合研究は、透明ボトムマイクロタイタープレート中、二つ組で(in duplicate)DMSO(最終濃度(conc)1%)中に希釈した10種の濃度の阻害剤(2濃度/ログ単位)を用いて室温で実施した。hCX3CR1受容体を発現する膜(最終濃度20μgタンパク質/ウェル)をSPAビーズ(最終濃度1mg/ウェル)と共に加え、すべてGTPγS結合緩衝液(50mMトリス−HCl,100mM NaCl,0.1%ゼラチン,15μgサポニン/mL及び3μM GDP,室温でpH7.4)中に懸濁した。最大刺激のため310pMフラクタルカインを添加する前に、膜、SPAビーズ及び薬物を30分プレインキュベートした。基礎活性は、フラクタルカイン刺激(GTPγS結合緩衝液)なしで見出される活性として定義した。さらに30分後、最終濃度0.1nM及び最終アッセイ体積0.2mLに[35S]GTPγSを添加して反応を開始した。30分後に2000rpmで2x5分間(異なる方向)遠心分離することによって実験を終了し、そして液体シンチレーションカウンター(Wallac MicroBeta(R) TriLux 1450)で放射活性を測定した。
本発明の化合物についての典型的なCX3CR1 Ki値は、約0.1〜約1000nMの範囲である。CX3CR1 Kiについての別の値は、約0.1nM〜約500nMの範囲である。CX3CR1 Kiについてのさらなる値は、約0.1nM〜約25nMの範囲である。最終的な化合物についてのインビトロhCX3CR1結合実験の結果を表1に示す。
Claims (24)
- nが1を表す、請求項1記載の化合物。
- R1がCH3を表す、請求項1記載の化合物。
- R2がハロ又はCNを表す、請求項1記載の化合物。
- R2がF又はClを表す、請求項1記載の化合物。
- R2がCNを表す、請求項1記載の化合物。
- nが1を表し;R1はCH3を表し;そしてR2は、F、Cl又はCNを表す、請求項1記載の化合物。
- ピリジンがその5−位に結合しており、そして2−位にClを有する、請求項1記載の化合物。
- ピリジンがその2−位に結合しており、そして4−位にCNを有する、請求項1記載の化合物。
- ピリジンがその2−位に結合しており、そして5−位にFを有する、請求項1記載の化合物。
- ピリジンがその2−位に結合しており、そして5−位にClを有する、請求項1記載の化合物。
- ピリジンがその2−位に結合しており、そして3−位にFを有する、請求項1記載の化合物。
- ピリジンがその4−位に結合しており、そして3−位にFを有する、請求項1の化合物。
- R3がHを表す、請求項1記載の化合物
- R4がCH3を表す、請求項1記載の化合物。
- 遊離塩基として、
5−{[(1S)−1−(5−クロロピリジン−2−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[(1S)−1−(5−フルオロピリジン−2−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[1−(3−フルオロピリジン−4−イル)エチル]チオ}−7{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[(1S)−1−(3−フルオロピリジン−4−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[(1R)−1−(3−フルオロピリジン−4−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
5−{[(1S)−1−(3−フルオロピリジン−2−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
2−{(1S)−1−[(7−{[(1R)−1−(ヒドロキシメチル)−3−メチルブチル]アミノ}−2−オキソ−2,3−ジヒドロ[1,3]チアゾロ[4,5−d]ピリミジン−5−イル)チオ]エチル}イソニコチノニトリル;
5−{[(1S)−1−(6−クロロピリジン−3−イル)エチル]チオ}−7−{[(1R)−1−(ヒドロキシメチル)ブチル]アミノ}[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;及び
5−{[(1S)−1−(6−クロロピリジン−3−イル)エチル]チオ}−7−[[(1R)−1−(ヒドロキシメチル)ブチル](メチル)アミノ][1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン;
から選ばれる化合物又はその医薬上許容しうる塩、溶媒和物若しくは塩の溶媒和物。 - 薬剤として使用するための請求項1〜16のいずれか1項に記載の化合物又はその医薬上許容しうる塩。
- 医薬上許容しうる希釈剤又は担体と混合された請求項1〜16のいずれか1項に記載の化合物又はその医薬上許容しうる塩。
- 多発性硬化症を治療又は予防する薬剤の製造における請求項1〜16のいずれか1項に定義された式(I)の化合物、又はその医薬上許容しうる塩の使用。
- プラークの組成を変えてプラーク破裂及びアテローム血栓症のイベントの危険性を軽減することによってアテローム性動脈硬化症を治療又は予防する薬剤の製造における請求項1〜16のいずれか1項に定義された式(I)の化合物又はその医薬上許容しうる塩の使用。
- 新しいアテローム硬化性病変又はプラークの形成を予防する及び/又は軽減することによって並びに/又は既存の病変及びプラークを予防する又は進行を遅らせることによってアテローム性動脈硬化症を治療又は予防する薬剤の製造における請求項1〜16のいずれか1項に定義された式(I)の化合物、又はその医薬上許容しうる塩の使用。
- 脳卒中又は一過性の脳損傷(TBI)を治療又は予防する薬剤の製造における請求項1〜16のいずれか1項に定義された式(I)の化合物、又はその医薬上許容しうる塩の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82746006P | 2006-09-29 | 2006-09-29 | |
US60/827,460 | 2006-09-29 | ||
US82812506P | 2006-10-04 | 2006-10-04 | |
US60/828,125 | 2006-10-04 | ||
PCT/SE2007/000857 WO2008039138A1 (en) | 2006-09-29 | 2007-09-27 | Novel 5, 7-disubstituted [1, 3 ] thiazolo [4, 5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010504962A JP2010504962A (ja) | 2010-02-18 |
JP5422386B2 true JP5422386B2 (ja) | 2014-02-19 |
Family
ID=39230456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009530308A Active JP5422386B2 (ja) | 2006-09-29 | 2007-09-27 | 新規な5,7−二置換された[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン誘導体及び治療におけるその使用 |
Country Status (22)
Country | Link |
---|---|
US (2) | US7960395B2 (ja) |
EP (1) | EP2069364B1 (ja) |
JP (1) | JP5422386B2 (ja) |
KR (1) | KR101345085B1 (ja) |
AR (1) | AR063023A1 (ja) |
AT (1) | ATE537177T1 (ja) |
AU (1) | AU2007300748B2 (ja) |
BR (1) | BRPI0717109A2 (ja) |
CA (1) | CA2664789A1 (ja) |
CL (1) | CL2007002813A1 (ja) |
CO (1) | CO6150165A2 (ja) |
ES (1) | ES2377469T3 (ja) |
HK (1) | HK1131389A1 (ja) |
IL (1) | IL197293A0 (ja) |
MX (1) | MX2009003005A (ja) |
NO (1) | NO20091579L (ja) |
NZ (1) | NZ576520A (ja) |
PE (1) | PE20080973A1 (ja) |
RU (1) | RU2441012C2 (ja) |
TW (1) | TW200820973A (ja) |
UY (1) | UY30612A1 (ja) |
WO (1) | WO2008039138A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR071036A1 (es) * | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
TWI543975B (zh) | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
JP5872105B2 (ja) | 2013-03-12 | 2016-03-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン−3−イル酢酸誘導体の塩およびその結晶 |
GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
AU2001232556A1 (en) * | 2000-02-11 | 2001-08-20 | Astrazeneca Ab | Pyrimidine compounds and their use as modulators of chemokine receptor activity |
SE0101082D0 (sv) | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
MXPA06003792A (es) * | 2003-10-07 | 2006-06-14 | Astrazeneca Ab | Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1. |
WO2006064228A2 (en) * | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | Thiazolopyramidine compounds for the modulation of chemokine receptor activity |
AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
-
2007
- 2007-09-21 TW TW096135626A patent/TW200820973A/zh unknown
- 2007-09-27 CA CA002664789A patent/CA2664789A1/en not_active Abandoned
- 2007-09-27 RU RU2009109100/04A patent/RU2441012C2/ru not_active IP Right Cessation
- 2007-09-27 NZ NZ576520A patent/NZ576520A/en unknown
- 2007-09-27 EP EP07835061A patent/EP2069364B1/en active Active
- 2007-09-27 JP JP2009530308A patent/JP5422386B2/ja active Active
- 2007-09-27 MX MX2009003005A patent/MX2009003005A/es active IP Right Grant
- 2007-09-27 ES ES07835061T patent/ES2377469T3/es active Active
- 2007-09-27 AR ARP070104275A patent/AR063023A1/es not_active Application Discontinuation
- 2007-09-27 US US11/862,743 patent/US7960395B2/en active Active
- 2007-09-27 UY UY30612A patent/UY30612A1/es not_active Application Discontinuation
- 2007-09-27 AT AT07835061T patent/ATE537177T1/de active
- 2007-09-27 BR BRPI0717109-9A patent/BRPI0717109A2/pt not_active IP Right Cessation
- 2007-09-27 AU AU2007300748A patent/AU2007300748B2/en not_active Ceased
- 2007-09-27 WO PCT/SE2007/000857 patent/WO2008039138A1/en active Application Filing
- 2007-09-27 KR KR1020097006362A patent/KR101345085B1/ko not_active IP Right Cessation
- 2007-09-28 PE PE2007001323A patent/PE20080973A1/es not_active Application Discontinuation
- 2007-09-28 CL CL200702813A patent/CL2007002813A1/es unknown
-
2009
- 2009-02-26 IL IL197293A patent/IL197293A0/en unknown
- 2009-03-05 CO CO09022856A patent/CO6150165A2/es unknown
- 2009-04-21 NO NO20091579A patent/NO20091579L/no not_active Application Discontinuation
- 2009-11-26 HK HK09111033.7A patent/HK1131389A1/xx not_active IP Right Cessation
-
2011
- 2011-01-19 US US13/009,384 patent/US20110105537A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2007300748B2 (en) | 2011-09-08 |
EP2069364B1 (en) | 2011-12-14 |
JP2010504962A (ja) | 2010-02-18 |
EP2069364A4 (en) | 2010-03-24 |
IL197293A0 (en) | 2009-12-24 |
CO6150165A2 (es) | 2010-04-20 |
TW200820973A (en) | 2008-05-16 |
CL2007002813A1 (es) | 2008-04-04 |
AU2007300748A1 (en) | 2008-04-03 |
CA2664789A1 (en) | 2008-04-03 |
NO20091579L (no) | 2009-04-21 |
AR063023A1 (es) | 2008-12-23 |
NZ576520A (en) | 2011-08-26 |
WO2008039138A1 (en) | 2008-04-03 |
WO2008039138A8 (en) | 2009-03-19 |
KR101345085B1 (ko) | 2013-12-31 |
ES2377469T3 (es) | 2012-03-27 |
MX2009003005A (es) | 2009-04-01 |
UY30612A1 (es) | 2008-05-02 |
PE20080973A1 (es) | 2008-10-02 |
HK1131389A1 (en) | 2010-01-22 |
US20080318981A1 (en) | 2008-12-25 |
EP2069364A1 (en) | 2009-06-17 |
RU2441012C2 (ru) | 2012-01-27 |
RU2009109100A (ru) | 2010-11-10 |
US20110105537A1 (en) | 2011-05-05 |
BRPI0717109A2 (pt) | 2013-10-08 |
US7960395B2 (en) | 2011-06-14 |
ATE537177T1 (de) | 2011-12-15 |
KR20090057069A (ko) | 2009-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101335055B1 (ko) | 신규한 5-치환된 7-아미노[1,3]티아졸로[4,5-d]피리미딘유도체 | |
RU2411245C9 (ru) | Новые производные 5,7-дизамещенного [1,3] тиазоло[4,5-d]пиримидин-2(3h)-она | |
JP2010504963A (ja) | 新規な5,7−二置換された[1,3]チアゾロ[4,5−d]ピリミジン−2(3h)−アミン誘導体及び治療におけるその使用 | |
JP5422386B2 (ja) | 新規な5,7−二置換された[1,3]チアゾロ[4,5−d]ピリミジン−2(3H)−オン誘導体及び治療におけるその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130403 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131015 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131112 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131125 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5422386 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |